Search results for "Anticoagulation"


 
Results 61 - 70 of about 588 for "Anticoagulation".
Sort by: Relevance | Newest | Oldest

Fewer than 1% of ED patients with syncope found to have PE in retrospective analysis

The findings should discourage the adoption of routine protocols for excluding pulmonary embolism (PE) in all patients presenting to the ED with syncope, the authors said.
https://acphospitalist.acponline.org/weekly/archives/2018/02/07/3.htm
7 Feb 2018

November 16, 2022

ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
https://acphospitalist.acponline.org/archives/2022/11/16/

Standardized rounds, antibiotics and acute kidney injury, and more

Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2017/06/in-the-news.htm
15 Jun 2017

Reports and recommendations on clot concerns with adenovirus COVID-19 vaccines

Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23.
https://acphospitalist.acponline.org/weekly/archives/2021/04/21/1.htm
21 Apr 2021

Adding contraception to the conversation

A hospitalist explains a recent call for her peers to consider their patients' family planning needs.
https://acphospitalist.acponline.org/archives/2022/07/06/free/adding-contraception-to-the-conversation.htm
6 Jul 2022

Latest research, recommendations cover diabetes, clots, and remdesivir in COVID-19

Mortality was lower in diabetes patients given sitagliptin at admission for COVID-19, ACP practice points support remdesivir, acquired thrombophilia does not predict clots, cardiac arrest survival is low, and admissions for other conditions were still way down over the summer.
https://acphospitalist.acponline.org/weekly/archives/2020/10/07/1.htm
7 Oct 2020

Rivaroxaban after discharge may reduce thromboembolic risk in medically ill

An industry-funded trial that gave medical patients rivaroxaban for 45 days after hospital discharge found decreased risk for a composite end point of symptomatic venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death compared to placebo.
https://acphospitalist.acponline.org/weekly/archives/2020/06/24/3.htm
24 Jun 2020

Major bleeding, mortality risks after VTE similar on DOACs or warfarin

The authors noted that the safety of DOAC treatment of VTE beyond 180 days remains uncertain and that 95% of DOAC users in the study were taking rivaroxaban, so further study of other agents is needed.
https://acphospitalist.acponline.org/weekly/archives/2017/10/25/3.htm
25 Oct 2017

COVID-19 research focuses on steroids, clots, hydroxychloroquine, zinc

Steroids' effects varied by C-reactive protein level, clots occurred despite prophylaxis, and hydroxychloroquine and zinc were ineffective for COVID-19, according to newly published studies.
https://acphospitalist.acponline.org/weekly/archives/2020/07/29/1.htm
29 Jul 2020

Therapeutic hypothermia, HAI network, and more

Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2020/05/recent-research.htm
15 May 2020

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next